No material corporate news briefings were recorded for Amgen Inc. in the 30 days preceding this report's generation date of 2026-06-25. Recent prior reports dated 2026-06-01, 2026-06-09, and 2026-06-17 similarly noted the absence of material corporate news events in their respective windows [Brief - 2026-06-17] [Brief - 2026-06-09] [Brief - 2026-06-01]. The current report is principally driven by notable institutional position changes recorded in recent 13F filings, supplemented by the most recent quarterly financial data available.
For the trailing twelve months ending 2026-03-31, Amgen recorded revenue of $37.22 billion, representing year-over-year growth of 5.76%. Net income for the same period stood at $7.80 billion, yielding a net margin of 20.96% and an operating margin of 28.39%. Gross margin was reported at 48.58%. Earnings per share grew 4.38% year-over-year. The company held $12.04 billion in cash against total debt of $59.32 billion. The trailing P/E ratio stood at 24.46, with a market capitalisation of approximately $189.67 billion [SEC 10-Q - AMGN - 2026-03-31].
Recent 13F filings revealed divergent institutional activity in Amgen. Bridgewater added 389% to its reported position, while Millennium added 47% to its holdings. Conversely, AQR Capital reduced its position by 30%, and Citadel reduced its position by 9.4% [SEC 13F - Bridgewater - Q1 2026] [SEC 13F - Millennium - Q1 2026] [SEC 13F - AQR Capital - Q1 2026] [SEC 13F - Citadel - Q1 2026]. No insider transaction data was provided for the current reporting period.
The prevailing macroeconomic rate environment shows the 10-year US Treasury yield at 4.50% and the 2-year yield at 4.16%, producing a normal yield curve with a spread of 34 basis points [FRED DGS10] [FRED DGS2]. These rate levels represent the broader fixed-income context against which Amgen's $59.32 billion total debt load is carried [SEC 10-Q - AMGN - 2026-03-31].
This report was generated in response to material institutional position changes identified across multiple 13F filings, specifically the substantial additions by Bridgewater and Millennium alongside reductions by AQR Capital and Citadel, all referencing the Q1 2026 reporting period.